In this context, SMP-105 TLR2 agonist has been proposed as an agent for the treatment of bladder cancer [110] and TAK-242 TLR4 antagonist has been shown to exhibit antitumor effect [111]. This evidence concerns the gene TLR2 and urinary bladder carcinoma.